Introduction {#Sec1}
============

**N**on-Hodgkin lymphoma (NHL) is the second most common primary malignancy in the sinonasal region, accounting for about 12--17% of all sinonasal cancers \[[@CR1]\]. The most two common subtypes of NHL associated with the sinonasal region are extranodal natural killer/T cell lymphoma (ENKTL) and diffuse large B cell lymphoma (DLBCL) \[[@CR1], [@CR2]\]. In geographical distribution, ENKTL of nasal type is the most common type of lymphoma in Asia and Latin America, whereas DLBCL is more common in Western countries \[[@CR1], [@CR2]\]. Originally, ENKTL arises predominantly from natural killer cell and DLBCL arises from mature B lymphocytes. Treatment strategies for the two histologic subtypes of lymphomas are different \[[@CR3]--[@CR5]\]. For sinonasal DLBCL, the chemotherapy treatment known as R-CHOP (rituximab-cyclophosphamide, doxorubicin, vincristine, and predisone) is most common \[[@CR3], [@CR4]\]. On the other hand, the current standard approach for sinonasal ENKTL is the non-anthracycline-containing chemotherapy with or without radiotherapy \[[@CR5]\]. Moreover, prognosis for ENKTL is worse than that for DLBCL due to its aggressive course with marked destructive capacity \[[@CR6], [@CR7]\]. Case-controlled disease-specific survival analysis showed that the 5-year disease-specific survival (DSS) for patients with sinonasal DLBCLs was 72.8%, compared with only 38.4% for patients with ENKTLs \[[@CR6]\]. Therefore, it is very important to differentiate sinonasal ENKTL from DLBCL for managing appropriate treatment plans to improve patient survival.

The differential diagnosis of sinonasal ENKTL and DLBCL can be highly challenging if it is only based on clinical signs and symptoms. The clinical presentation of patients with sinonasal ENKTL or DLBCL is nonspecific, mimicking allergic rhinitis and upper respiratory infection \[[@CR7]\]. Furthermore, the diagnostic performance of biopsy for sinonasal lymphoma is poor due to an uncertainty whether correct tissue is sampled \[[@CR8]\]. One main reason is because that sinonasal ENKTL formerly known as lethal midline granuloma may present with a necrotizing and angiodestructive growth pattern, and an extensive coagulative necrosis in the tumor can be misdiagnosed as inflammatory process \[[@CR8]\]. According to a previous study, the sensitivity of endoscopic incisional biopsy in differential diagnosis of necrotizing sinonasal lesions is extremely low \[[@CR9]\].

Magnetic resonance imaging (MRI) has been proven to play crucial roles in the differential diagnosis of sinonasal tumors \[[@CR10], [@CR11]\], especially for classification of the lymphoma and squamous cell carcinoma \[[@CR12]--[@CR14]\]. Previous studies reported that the homogenous signal intensity, facial soft tissue involvement, and low ADC values on MR findings suggested the diagnosis of the lymphomas \[[@CR12]--[@CR14]\]. However, whether these features can help in differential diagnosis of lymphoma subtypes is still unclear. To our knowledge, only a few studies discussed the usefulness of DWI values combined with other MRI parameters in differential diagnosis of ENKTL and DLBCL \[[@CR15]\].

The purpose of this current study was to evaluate whether conventional MR imaging features can differentiate sinonasal ENKTL from DLBCL.

Materials and methods {#Sec2}
=====================

Study approval was granted by the institutional review board and the informed consent was waived for this retrospective study.

Patients {#Sec3}
--------

This retrospective study included consecutive MRI scans of 59 patients (41 men and 18 women; mean age 46 ± 15 years) with sinonasal ENKTL and 27 patients (16 men and 11 women; mean age 66 ± 13 years) with sinonasal DLBCL examined during February 2011 and November 2018. Inclusion criteria: (1) sinonasal mass demonstrated at MRI proved to be ENKTL or DLBCL by pathologic examination and (2) the MRI scans were performed prior to the biopsy or any treatments such as radiotherapy or chemotherapy. MRI scans with either a recurrent ENKTL or DLBCL were excluded from this study.

MR protocol {#Sec4}
-----------

Conventional MRI scans were performed in 36 patients with GE HDxt 3.0-T MR scanner (GE Healthcare, Milwaukee, WI) and 50 patients with 3.0-T Discovery 750 scanner (GE Healthcare, Milwaukee, Wisconsin, USA) by using an 8-channel head coil. Pre-contrast axial T1WI and T2WI as well as post-contrast fast spin echo (FSE) T1WI on axial, coronal, and sagittal view were performed in all patients. The parameters were as follows: FSE T1WI (TR 600\~700 ms,TE 10 ms, matrix 320 × 256), FSE T2WI (TR 3900\~4300 ms, TE 90 ms, matrix 512 × 256), FOV 20 × 20 cm, slice thickness 4\~5 mm, gap 1 mm. Gadopentetate dimeglumine contrast agent (Magnevist; Bayer Schering, Berlin,Germany) was administered intravenously (0.1 mmol/kg) at a flow rate of 2 mL/s, followed by a 20-mL saline flush.

Imaging analysis {#Sec5}
----------------

Imaging features per each sinonasal ENKTL or DLBCL on 86 MRI scans were indicated by two experienced radiologists independently (\*\*X.Y.W. and Y.C\*\*, with 10 and 16 years of experience in head and neck imaging, respectively), without the information of final pathology diagnosis. The MRI imaging features of the tumors included side, location, margin, pre-contrast T1 and T2 signal intensity and homogeneity, post-contrast enhancement degree and homogeneity, septal enhancement pattern, internal necrosis, mass effect, and adjacent involvements. Three levels of the enhancement degree were defined as (1) mild (similar to adjacent muscles except extraocular muscles), (2) moderate (greater than muscles), and (3) marked (similar to or greater than nasal mucosa). Further, a septal enhancement pattern was considered if partially or diffusely marked enhanced striations could be seen within lower- or non-enhanced components of the tumor on delayed contrast T1WI (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1An example for the septal enhancement pattern. Axial delayed contrast T1WI shows marked enhanced striations (arrows) within mild enhanced solid components of the tumor

Statistical analysis {#Sec6}
--------------------

All statistical analyses were performed with the IBM SPSS 20.0 software. Differences in MRI features between ENKTL and DLBCL were determined by Chi-square test or Fisher's exact test. The *P* value less than 0.05 was considered significant. Inter-reader reproducibility of all evaluated MRI features was evaluated by kappa analysis. The kappa values were interpreted as \< 0.40, poor; 0.41--0.60, moderate; 0.61--0.80, good; and \> 0.81, excellent. Multivariate logistic regression analysis was applied to evaluate MRI-based performance in the differential diagnosis of sinonasal ENKTL and DLBCL.

Results {#Sec7}
=======

MR imaging features of sinonasal ENKTL and DLBCL and interobserver agreement between observers 1 and 2 are shown in Table [1](#Tab1){ref-type="table"}. Significant differences were found in location, margin, T1 and T2 homogeneity, degree of enhancement, enhancement homogeneity, septal enhancement pattern, mass effect, internal necrosis, and adjacent structure involvements (all *P* \< 0.03). All the ENKTLs were located in the nasal cavity, whereas DLBCLs were more often located in the paranasal sinuses (67%). Furthermore, ill-defined margin, marked enhancement, heterogeneous signal intensity, internal necrosis, less mass effect, and ala nasi involvement were often seen in sinonasal ENKTL (Fig. [2](#Fig2){ref-type="fig"}), whereas homogenous signal intensity, mild enhancement, septal enhancement pattern, and intracranial and orbital involvements were often seen in sinonasal DLBCL (Fig. [3](#Fig3){ref-type="fig"}).Table 1MRI features of sinonasal extranodal NK/T cell lymphomas and diffuse large B cell lymphomasENKTL (*n* = 59)DLBCL (*n* = 27)No.%No.%No. of patients5910027100Side0.4501Left1729830Right17291141Bilateral2542830Location*0.000*0.964Nasal cavity59100933Paranasal sinus001867Margin*0.000*0.757Well defined6101970Ill defined5390830T1 signal intensity0.7020.845Hypointense58311Isointense54922489T1 homogeneity*0.027*0.54Homogenous39662489Heterogeneous2034311T2 signal intensity0.8670.691Hypointense5827Isodense54922593Hyperintense0027T2 homogeneity*0.003*0.624Homogenous28472281Heterogeneous3153519Degree of enhancement*0.000*0.785Mild7121037Moderate32541763Marked203400Enhancement homogeneity*0.000*0.696Homogenous10172074Heterogeneous4983726Septal enhancement pattern*0.000*0.729Yes001141No591001659Internal necrosis*0.000*0.803Yes5085415No9152385Mass effect*0.000*0.720Yes16272281No4373519Facial soft tissue involvement0.4330.678Yes21361244No38641556Intracranial involvement*0.000*0.849Yes23933No57971867Orbital involvement*0.000*0.854Yes6101867No5390933Nasopharynx involvement0.3100.673Yes1729519No42712281Ala nasi involvement*0.000*0.878Yes4475830No1525933*ENKTL* extranodal NK/T cell lymphomas, *DLBCL* diffuse large B cell lymphomaFig. 2MRI features in a 67-year-old man with pathologically proven extranodal natural killer/T cell lymphoma (ENKTL) in the sinonasal region. a Axial T1-weighted MR image shows diffuse subcutaneous soft tissue thickening (small short arrows) in the bilateral nasal cavities and nasopharynx and an elongated mass (arrow) in the left nasal cavity with heterogeneous signal intensity. **b** Axial T2-weighted MR image shows a heterogeneous isointense tumor (arrow) with hypointense foci. **c**, **d** Axial (**c**) and coronal (**d**) contrast-enhanced T1-weighted MR images show the thickening subcutaneous soft tissue (small short arrows) with marked enhancement; no enhancement part was considered as the internal necrosis (small long arrows)Fig. 3MRI features in a 46-year-old man with diffuse large B cell lymphoma in the sinonasal region. **a** Axial T1-weighted MR image shows a homogeneously isointense mass in left nasal cavity and maxillary sinus. **b** Axial T2-weighted MR image shows the tumor with homogeneous isointensity. **c**, **d** Axial (c** a**) and coronal (**d**) contrast-enhanced T1-weighted MR images show heterogeneous enhancement of the tumor with the septal enhancement pattern (small long arrows) and the involvement of the skull and left orbit (small short arrows)

Using a combination of location, internal necrosis, and septal enhancement pattern in multivariate logistic regression analysis, sensitivity, specificity, and accuracy in differential diagnosis of ENKTL and DLBCL were 100%, 79.4%, and 91.9%, respectively, for radiologist 1, and were 98.3%, 81.5%, and 93.0%, respectively, for radiologist 2.

Discussion {#Sec8}
==========

Some previous studies reported that due to nonspecific physical and radiological features, a definitive diagnosis of NEKTL was challenged in clinical practice, and it usually required repeat and deep biopsy \[[@CR16]\]. In the current study, we analyzed MRI features for consecutive 59 patients with ENKTL compared with 27 patients with DLBCL. We found that MRI features showed a reliable and high diagnostic accuracy in differential diagnosis of sinonasal ENKTL and DLBCL.

The sinonasal ENKTL is generally a highly aggressive tumor characterized by vascular damage and destruction \[[@CR7]\]. The prognosis of ENKTL is very poor, with 5-year disease-specific survival of about 31\~46% \[[@CR6], [@CR17]\]. On the other hand, DLBCL has a better prognosis regardless of gender, stage, and age. Based on different prognoses and treatment strategies, we tried to differentiate ENKTL from DLBCL by MRI in this study.

The most useful three features for differential diagnosis of sinonasal ENKTL and DLBCL were the location, internal necrosis, and septal enhancement pattern from our study. Some previous studies reported that most sinonasal ENKTLs were located in the nasal cavity \[[@CR15], [@CR18]\]. Consistent to previous studies, all of the 59 ENKTLs in our study were located in the nasal cavity. However, if a tumor is located in the paranasal sinus, the possible diagnosis may be a DLBCL rather than an ENKT. Internal necrosis was more commonly found in ENKTL (85%) than that in DLBCL (15%). Pathological reasons include that the ENKTL has the angiocentric and angiodestructive growth pattern that can easily cause the coagulative necrosis and ulcer, whereas the DLBCL has been characterized by sheets of large cleaved and/or noncleaved cells \[[@CR19]\]. Septal enhancement pattern was found in 41% of DLBCLs, while none of ENKTLs. The similar MRI enhancement pattern has been previously reported on malignant lymphomas of the ovary and breast \[[@CR20], [@CR21]\]. We believe that this septal enhancement pattern could be not specific for sinonasal DLBCL only, but also might be for some other small round cell tumors that were attributed to fibrous bands.

A previous study by He et al. reported that the significant differences were found in degree of MRI enhancement between sinonasal ENKTL and DLBCL \[[@CR15]\]. However, we found that the enhanced degree showed a significant higher prevalence of "marked enhancement" in ENKTLs compared with DLBCLs, whereas the previous study reported that the enhancement was less intense for their ENKTLs. The reasons for this are probably because of different evaluation methods or some bias in subjective observations. We only evaluated the solid part of tumors for the enhancement degree levels (no evaluation for possible necrosis part) in this study.

Our study showed that sinonasal ENKTL tended to have less mass effect than DLBCL (27% versus 81%), which is similar to primary lymphomas in central nervous system \[[@CR22]\]. The reason should be because the ENKTL usually diffusely infiltrate along the walls of the nasal cavity, enveloping the nasal turbinate and nasal septum with no obvious mass effect. As same as the adjacent involvement reported by a previous study \[[@CR15]\], the prevalence of intracranial or orbit involvements was lower in sinonasal ENKTL than that in DLBCL in our study. Sinonasal ENKTLs located in the nasal cavity with earlier nasal symptoms were more often diagnosed at an early stage, whereas DLBCLs hidden in the paranasal sinuses were more often diagnosed at a late stage \[[@CR23]\]. In addition, DLBCL located in the paranasal sinuses was much nearer to the skull and preferred to show intracranial involvement.

Our study had several limitations. First, in our consecutive series, the patients with pathology-proven primary sinonasal DLBCL were relatively a small patient set compared to contemporaneous patients with the ENKTL, and it might cause that only three MRI features could be used in the multiple logistic regression analysis. Second, although bone destruction could be an imaging feature of sinonasal ENKTL suggested by other studies, this feature was not evaluated in this study because we were considering the limited value of MRI in evaluation of bone changes. Finally, the MRI examinations were acquired using two different MRI systems.

Conclusion {#Sec9}
==========

MRI can effectively differentiate ENKTL from DLBCL in the sinonasal region with a high diagnostic accuracy. Sinonasal ENKTL should be considered for differential diagnosis if an ill-defined tumor in the nasal cavity shows moderate-significant enhancement with internal necrosis, less mass effect, or ala nasi involvement.
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